Patients
Why “rare disease” is a regulatory label, not a patient real...
Regulators define a rare disease by how many people have it, and the answer depends on who is counting.
Digital
Sponsored
4 Questions pharma leaders can’t skip before letting AI act
Nataliya Andreychuk explains what teams must do before letting AI act on their behalf, and how that groundwork becomes a competitive advantage.
Digital
AI, start-ups, and the future of human health: AION Labs’ Ma...
In a new episode of the pharmaphorum podcast, Nicole Raleigh invites Mati Gill, CEO of AION Labs, back as guest.
R&D
Reliability in life sciences logistics: What good looks like
What constitutes a reliable supply chain is changing rapidly.
Oncology
How AI is advancing patient subgroup identification in oncol...
With the advent of AI, it’s now possible to enrich clinical trials for patient subgroups more precisely than ever before.
Sales & Marketing
Digital
Market Access
Editor's Picks
Editor's Picks
